業績集 | accountancy-firm-j2

業績集(publication list)

原著論文 (original article)

Maeda Y, Toyoda M, Kuwata T, Terasawa H, Tokugawa U, Monde K, Sawa T, Ueno T, Matsushita S. (2024) Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2. Int J Mol Sci 25, 1353
Maeda Y, Monde K, Terasawa H, Tanaka Y, and Sawa T (2023) Interaction of TSG101 with the PTAP Motif in Distinct Locations of Gag Determines the Incorporation of HTLV-1 Env into the Retroviral Virion. Int J Mol Sci 24,16520
Tahara Y, Fujita M, Zhang T, Wang D, Tateishi H, Togami A, Nyame P, Terasawa H, Monde N, Appiah-Kubi J, Amesimeku WO, Alsaadi DHM, Wada M, Sugimura K, Gezici S, Ciftci H, Karahan F, Sekeroglu N, Otsuka M, Sawa T, Maeda Y, Watanabe T, Monde K (2023) Turkish Plants, Including Quercetin and Oenothein B, Inhibit the HIV-1 Release and Accelerate Cell Apoptosis. Biological and Pharmaceutical Bulletin 46 (11): 1535. doi: 10.1248/bpb.b23-00328
Iwasaki-Hozumi H, Maeda Y, Niki T, Chagan-Yasutan H, Bai G, Matsuba T, Furushima D, Ashino Y, Hattori T (2023)　Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab. Int J Mol Sci 10;24(4):3591. doi:10.3390/ijms24043591
Nguyen HT, Kuse N, Zhang Y, Murakoshi H, Maeda Y, Tamura Y, Maruyama R, Tran GV, Nguyen TV, Nguyen KV, Oka S, Chikata T, Takiguchi M (2022) Control of HIV-1 Replication by CD8+ T Cells Specific for Two Novel Pol Protective Epitopes in HIV-1 Subtype A/E Infection. J Virol 96(19):e0081122. doi: 10.1128/jvi.00811-22.
Monde K, Satou Y, Goto M, Uchiyama Y, Ito J, Kaitsuka T, Terasawa H, Monde N, Yamaga S, Matsusako T, Wei FY, Inoue I, Tomizawa K, Ono A, Era T, Sawa T, Maeda Y (2022) Movements of ancient human endogenous retroviruses detected in SOX2-expressing cells. J Virol 11;96(9):e0035622. doi: 10.1128/jvi.00356-22.
Kaku Y, Kuwata T, Zahid HM, Hashiguchi T, Noda T, Kuramoto N, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Shimura K, Onishi C, Muramoto Y, Suzuki T, Sasaki J, Nagasaki Y, Minami R, Motozono C, Toyoda M, Takahashi H, Kishi H, Fujii K, Tatsuke T, Ikeda T, Maeda Y, Ueno T, Koyanagi Y, Iwagoe H, Matsushita S (2021) Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Rep 36(2):109385. doi: 10.1016/j.celrep.2021.109385
Bai G, Furushima D, Niki T, Matsuba T, Maeda Y, Takahashi A, Hattori T, Ashino Y (2021) High levels of the cleaved form of galectin-9 and osteopontin in the plasma are associated with inflammatory markers that reflect the severity of COVID-19 pneumonia. Int J Mol Sci 22(9), 4978. doi.org/10.3390/ijms22094978
Padilla ST, Niki T, Furushima D, Bai G, Chagan-Yasutan H, Telan EF, Tactacan-Abrenica RJ, Maeda Y, Solante R, Hattori T (2020) Plasma Levels of a Cleaved Form of Galectin-9 Are the Most Sensitive Biomarkers of Acquired Immune Deficiency Syndrome and Tuberculosis Coinfection. Biomolecules 10, 1495
Maeda Y, Takemura T, Chikata T, Kuwata T, Terasawa H, Fujimoto R, Kuse N, Akahoshi T, Murakoshi H, Van Tran G, Zhang Y, Pham CH, Pham AHQ, Monde K, Sawa T, Matsushita S, Nguyen TV, Van Nguyen K, Hasebe F, Yamashiro T, Takiguchi M (2020) Existence of replication-competent minor variants with different coreceptor usage in plasma from HIV-1-infected individuals. J. Virol. 94 e00193-2
前田洋助: HIV-1コレセプター発見によってもたらされたHIV-1感染治療と治癒　臨床とウイルス 2019, 47, 69-76
Hamada K, Maeda Y, Mizutani A, Okada S (2019) The Phosphatidylinositol 3-Kinase p110α/PTEN Signaling Pathway Is Crucial for HIV-1 Entry. Biol Pharm Bull 42, 130-138
Thida W, Kuwata T, Maeda Y, Yamashiro T, Tran GV, Nguyen KV, Takiguchi M, Gatanaga H, Tanaka K, Matsushita S (2019) The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses. Biochem Biophys Res Commun 508, 46-51
Tateishi H, Monde K, Anraku K, Koga R, Hayashi Y, Ciftci HI, DeMirci H, Higashi T, Motoyama K, Arima H, Otsuka M, Fujita M (2017) A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis". Sci Rep. 7:8957. doi: 10.1038/s41598-017-09129-w.
Monde K, Terasawa H, Nakano Y, Soheilian F, Nagashima K, Maeda Y, Ono A (2017) Molecular mechanisms by which HERV-K Gag interferes with HIV-1 Gag assembly and particle infectivity. Retrovirology 14, 27
Maeda Y, Terasawa H, Tanaka Y, Mitsuura C, Nakashima K, Yusa K, Harada S (2015) Separate cellular localizations of human T-tropic virus 1 (HTLV-1) Env and glucose transporter 1 (GLUT1) are required for HTLV-1-mediated fusion and infection. J Virol 89, 502-511
Maeda Y, Terasawa H, Nakano Y, Monde K, Yusa K, Oka S, Takiguchi M, Harada S (2014) V3-independent competitive resistance of a dual-X4 HIV-1 to the CXCR4 inhibitor AMD3100. PloS One e89515
Nakano Y, Monde K, Terasawa H, Yuan Y, Yusa K, Harada S, Maeda Y (2014) Preferential recognition of monomeric CCR5 expressed in cultured cells by the HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1. Virology 452-453, 117-124
Suzuki K, Hattori S, Marks K, Ahlenstiel C, Maeda Y, Ishida T, Millington M, Boyd M, Symonds G, Cooper DA, Okada S, Kelleher A (2013) Promoter targeting RNA suppresses HIV-1 infection in vivo through transcriptional gene silencing. Molecular Therapy Nucleic Acids e137
Yuan Y, Yokoyama K, Maeda Y, Terasawa H, Harada S, Sato Y, Yusa K (2013) Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1JR-FL to maraviroc. PloS One 8: e65115
Toda T, Kuwahara K, Kondo N, Matsuda Z, Maeda Y, Maeda K, Sakaguchi N (2012) Dynamic appearance of antigenic epitopes effective for viral neutralization during membrane fusion initiated by interactions between HIV-1 envelope proteins and CD4/CXCR4. Immunobiology 217:864-872
Yuan Y, Maeda Y, Terasawa H, Monde K, Harada S, Yusa K (2011) A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology 413, 293-299
Maeda Y, Yoshimura K, Miyamoto F, Kodama E, Harada S, Yuan Y, Harada S, Yusa K (2011) In vitro and In vivo Resistance to Human Immuno Deficiency Virus Type 1 Entry Inhibitors. J AIDS Clinic Res S2:004. doi:10.4172/2155-6113.S2-004
Maeda Y, Yusa K, Nakano Y, Harada S (2011) Involvement of inhibitory factors in the inefficient entry of HIV-1 into the human CD4 positive HUT78 cell line. Virus Res 155, 368-371
Harada S, Monde K, Tanaka Y, Kimura T, Maeda Y, Yusa K (2008) Neutralizing antibodies decrease the envelope fluidity of HIV-1. Virology 370:142-50
Ikeda T, Ohsugi T, Kimura T, Matsushita S, Maeda Y, Harada S, Koito A (2008) The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acid Res 36:6859-6871
Maeda Y, Yusa K, and Harada S (2008) Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antiviral Res 77:128-135
Harada S, Monde K, Tanaka Y, Kimura T, Maeda Y, Yusa K (2008) Neutralizing antibodies decrease the envelope fluidity of HIV-1. Virology 370:142-150
Monde K, Maeda Y, Tanaka Y, Harada S, Yusa K (2007) Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion incorporated CCR5. J Biol Chem 282:36923-36932
Harada, S, Yokomizo K, Monde K, Maeda Y, Yusa K (2007) A broad antiviral neutral glycolipid, fattiviracin FV-8, is a membrane fluidity modulator. Cell Microbiol 9:196-203
Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S (2006) Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 20:2065-2073
Yusa K, Maeda Y, Fujioka, A, Monde K, Harada S (2005) Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 280:30083-30090
Harada S, Yusa K, Monde K, Akaike T, Maeda Y (2005) Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem Biophys Res Commun 329:480-6
Abdel-Wahab MSE, Foda M, Gamil MA, El-salakawy A, El-Attar G, Harada S, Maeda Y (2004) Possible association between the chemokine receptor gene CCR5-delta32 mutation and hepatitis C virus pathogenesis. Egypt J Hosp Med 17:58-62
Song W, Maeda Y, Tenpaku A, Harada S, Yusa K (2004) Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations. Antiviral Res 61:173-180
Harada S, Akaike T, Yusa K, Maeda Y (2004) Adsorption and infectivity of human immunodeficiency virus type 1 are modified by the fluidity of the plasma membrane for multiple-site binding. Microbiol Immunol 48:347-355
Harada S, Yusa K, Maeda Y (2004) Heterogeneity of envelope molecules shown by different sensitivities to anti-V3 neutralizing antibody and CXCR4 antagonist regulates the formation of multiple-site binding of HIV-1. Microbiol Immunol 48:357-365
Maeda Y, Yusa K, Harada S (2003) Enhanced infectivity of HIV-1 by X4 HIV-1 coinfection. Biochem Biophys Res Commun 308:906-913
Kimura T, Yoshimura K, Nishihara K, Maeda Y, Matsumi S, Koito A, Matsushita S (2002) Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J Infect Dis 185:53-60
Tempaku, A, Maeda Y, Song W, Harada S (2001) Human T-cell leukemia virus type-I (HTLV-I) tax is not the only one factor to enhance human immunodeficiency virus type-I (HIV-1) infection in culture-supernatants. Virus Genes 23:77-80
Song W, Yahara S, Maeda Y, Yusa K, Tanaka Y, Harada S (2001) Enhanced infection of an X4 strain of HIV-1 due to capping and colocalization of CD4 and CXCR4 induced by capsianoside G, a diterpene glycoside. Biochem Biophys Res Commun 283:423-429
Foda M, Harada S, Maeda Y (2001) Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity. Microbiol Immunol 45:521-530
Tsurutani N, Kubo M, Maeda Y, Ohashi T, Yamamoto N, Kannagi M, Masuda T (2000) Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J Virol 74:4795-4806
Maeda Y, Foda M, Matsushita S, Harada S (2000) Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol 74:1787-1793

業績集(publication list)

原著論文 (original article)

Harada S, Monde K, Tanaka Y, Kimura T, Maeda Y, Yusa K (2008) Neutralizing antibodies decrease the envelope fluidity of HIV-1. Virology 370:142-150

Monde K, Maeda Y, Tanaka Y, Harada S, Yusa K (2007) Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion incorporated CCR5. J Biol Chem 282:36923-36932

Song W, Yahara S, Maeda Y, Yusa K, Tanaka Y, Harada S (2001) Enhanced infection of an X4 strain of HIV-1 due to capping and colocalization of CD4 and CXCR4 induced by capsianoside G, a diterpene glycoside. Biochem Biophys Res Commun 283:423-429

Foda M, Harada S, Maeda Y (2001) Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity. Microbiol Immunol 45:521-530

Tsurutani N, Kubo M, Maeda Y, Ohashi T, Yamamoto N, Kannagi M, Masuda T (2000) Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J Virol 74:4795-4806

Maeda Y, Foda M, Matsushita S, Harada S (2000) Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol 74:1787-1793